Dr. Bhaskar Roy, MBBS
Physical Medicine & Rehabilitation (PM&R) (Neuromuscular Medicine (Psychiatry & Neurology) Physician)
- Medicare participating
At a glance
- Years since graduation
- 18
- In the NPI registry since
- 2012
- Medicare patients seen, 2024
- 158
Licensed in Connecticut since 2017, according to the Connecticut Department of Public Health. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2012Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neuromuscular Medicine (Psychiatry & Neurology) Physician primary
CT license 56713 (first issued 2017; active) -
Behavioral Neurology & Neuropsychiatry Physician
CT license 56713 (first issued 2017; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Map: Physical Medicine & Rehabilitation (PM&R) per capita by county →
Where they work
Hospitals
- Yale-New Haven Hospital New Haven, CT
- Bridgeport Hospital Bridgeport, CT
Medical groups
- Yale University (2,645 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 158
- Services billed
- 362
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 50 | 15 |
| Established patient office or other outpatient visit, 30-39 minutes | 46 | 37 |
| Needle measurement of electrical activity in arm or leg muscles, limited study | 41 | 21 |
| Established patient office or other outpatient visit, 20-29 minutes | 40 | 31 |
| Needle measurement of electrical activity in arm or leg muscles, complete study | 17 | 14 |
| Hospital discharge day management, 30 minutes or less | 14 | 14 |
| New patient office or other outpatient visit, 30-44 minutes | 11 | 11 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 11 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Gabapentin Other prescribers in New Haven, CT | 120 |
| Privigen (immun glob g(igg)/pro/iga 0-50) | 74 |
| Gammagard Liquid (immun glob g(igg)/gly/iga ov50) | 49 |
| Pregabalin Other prescribers in New Haven, CT | 47 |
| Gamunex-C (immune globul g/gly/iga avg 46) | 37 |
| Baclofen Other prescribers in New Haven, CT | 23 |
| Hizentra (immun glob g(igg)/pro/iga 0-50) | 18 |
| Prednisone Other prescribers in New Haven, CT | 18 |
| Mycophenolate Mofetil Other prescribers in New Haven, CT | 12 |
| Neurontin (gabapentin) Other prescribers in New Haven, CT | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $6,590 in total to this clinician.
| Genzyme Corporation | $6,590 |
|---|
| Consulting Fee | $6,590 |
|---|
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Genzyme Corporation May 30, 2025 | Consulting Fee | $6,590 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 9 industry-funded studies in 2025, from 5 companies. The companies reported $363,639 in research payments for these studies, mostly to the institutions running them.
- A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Imm…
Argenx US, Inc. - A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work
Sanofi US Services Inc. · Active, not recruiting · NCT06290128 - A Study of HyQvia in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) in Routine Clinical Care
Takeda Pharmaceuticals U.S.A., Inc. - A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Sanofi US Services Inc. · Recruiting · NCT06290141 - A Phase 3, Single-Arm, Multicenter, Open-label Extension of Study ARGX-113-2007 to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Acti…
Argenx US, Inc. - A Multicenter, Parallel-group, Double-blind, 2-Arm, Phase III Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared with Placebo Adde…
AstraZeneca Pharmaceuticals LP - A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies (SPIREA)
Janssen Research & Development, LLC - A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants with Primary Immune Thrombocytopenia
Argenx US, Inc. - A Phase 3 Single Arm Study to Evaluate the Efficacy, Safety, and Tolerability of Immune Globulin Subcutaneous (Human), 20% Solution with Recombinant Human Hyaluronidase (TAK-881) for the Treatment of Chronic Inflamm…
Takeda Pharmaceuticals U.S.A., Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.